CLEAR LABELS Act
Sponsored By: Senator Scott, Rick [R-FL]
In Committee
Summary
**This bill would require drug labels to disclose the *original manufacturer and supply‑chain information* for active ingredients and finished products.** It would force labels to show names, places of business, and unique facility identifiers or provide a scannable link to a searchable portal with that data.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
New drug labels list original makers
This bill would require labels and certificates to show who originally made active drug ingredients and finished drugs. For active ingredients, labels and certificates would list the original manufacturer's name, place of business, and a unique facility identifier. For finished drugs, labels would identify the original maker of each active ingredient, the original finished-product manufacturer, and the packer or distributor, or provide a link, barcode, or QR code to a searchable portal with that data. If there are multiple possible API makers, listing all of them in the label or portal would meet the rule. Manufacturers, packers, or distributors would also have to give the information in paper form or a package insert on request. The Secretary would write implementing rules, which could allow reasonable variations and would take effect no earlier than one year after the final rules are published and apply to drugs made on or after that date.
No extra origin mark for drugs
This bill would add an exemption so finished drug products marked under the new FDA labeling rule would not need separate country-of-origin marks under the Tariff Act. The exemption would apply only to finished drugs that meet the FDA labeling standard. The change would take effect when the law is enacted.
Sponsors & CoSponsors
Sponsor
Scott, Rick [R-FL]
FL • R
Cosponsors
Sen. Gillibrand, Kirsten E. [D-NY]
NY • D
Sponsored 2/5/2026
Sen. Tuberville, Tommy [R-AL]
AL • R
Sponsored 2/5/2026
Katie Britt
AL • R
Sponsored 2/5/2026
Ron Johnson
WI • R
Sponsored 2/5/2026
Sen. Moody, Ashley [R-FL]
FL • R
Sponsored 2/12/2026
Sen. Lee, Mike [R-UT]
UT • R
Sponsored 3/9/2026
Sen. Cramer, Kevin [R-ND]
ND • R
Sponsored 3/11/2026
Sen. Risch, James E. [R-ID]
ID • R
Sponsored 3/23/2026
Sen. Grassley, Chuck [R-IA]
IA • R
Sponsored 3/25/2026
Sen. Ricketts, Pete [R-NE]
NE • R
Sponsored 3/25/2026
Sen. Ernst, Joni [R-IA]
IA • R
Sponsored 4/13/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov